Biogen introduces multiple sclerosis support program
Biogen Inc., Cambridge, MA, introduced a new support program to help patients, their care partners and health care professionals manage multiple sclerosis.
Biogen Inc., Cambridge, MA, introduced a new support program to help patients, their care partners and health care professionals manage multiple sclerosis.
The company manufactures Avonex® (Interferon beta-la), a product used in the treatment of relapsing forms of multiple sclerosis.
The Avonex AllianceSM was designed to complement the company's existing services for MS patients. Biogen already offers special pharmacy and home delivery options, a telephone support line, a free injection training program and reimbursement counseling.
The new program is intended to enhance Avonex therapy by providing patients with support tools.
Participating members will receive a periodic newsletter with articles and updates about the disease and their medication, as well as other informational mailings. They will also receive a voucher for free needles and syringes and a video in which other patients battling MS share their experiences with therapy.
Enrollment in the program is free and available to all people with MS, regardless of whether they are using Avonex.
This is the second support program designed recently for patients with multiple sclerosis. Last month, Teva Marion Partners, Kansas City, MO, launched a disease management program in conjunction with a nationwide survey that found that one-quarter of people with MS surveyed felt they were not getting the emotional support and understanding they need. PR
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
